Literature DB >> 12435687

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.

Erika J Ernst1, Ellen E Roling, C Rosemarie Petzold, Douglas J Keele, Michael E Klepser.   

Abstract

We evaluated the in vitro activity of the new echinocandin antifungal micafungin against Candida spp. using microdilution and time-kill methods. Additionally, we examined the postantifungal effect (PAFE) of micafungin. Finally, we evaluated the effect of the addition of serum and plasma on the MIC of micafungin. Four Candida albicans isolates and two isolates of each Candida glabrata, Candida krusei, and Candida tropicalis were selected for testing. The MICs of micafungin were determined in RPMI 1640 medium buffered with morpholinepropanesulfonic acid alone and with the addition of 10, 20, and 50% human serum and plasma. MICs were determined by using two endpoints: a prominent reduction in growth (the MIC at which 80% of isolates are inhibited [MIC(80)]) and complete visual inhibition of growth (MIC(100)). The minimum fungicidal concentration (MFC) of micafungin for each isolate was also determined. Time-kill curves were determined for each isolate in RPMI 1640 medium with micafungin at concentrations ranging from 0.125 to 16 times the MIC(80) to assess the correlation between MIC(80) and fungicidal activity. PAFE studies were conducted with each isolate by using concentrations ranging between 0.25 and 4 times the MIC(80). The MIC(80)s for the test isolates ranged from 0.0039 to 0.25 micro g/ml. Overall, the addition of serum or plasma increased the MIC 6 to 7 doubling dilutions for C. albicans and 3 to 4 doubling dilutions for C. krusei and C. tropicalis. Micafungin time-kill studies demonstrated fungicidal activity at concentrations ranging from 4 to 16 times the MIC(80). Micafungin is very potent agent against a variety of Candida spp., producing fungicidal activity against 7 of 10 isolates tested. A PAFE was observed against all isolates. The PAFE was influenced by the drug concentration, with the highest concentration resulting in the longest observed PAFE in each case. The highest concentration tested, four times the MIC, resulted in a PAFE of more than 9.8 h for 5 of 10 isolates tested (range, 0.9 to > or =20.1 h).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435687      PMCID: PMC132786          DOI: 10.1128/AAC.46.12.3846-3853.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

Authors:  M E Klepser; E J Wolfe; R N Jones; C H Nightingale; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

2.  Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods.

Authors:  M E Klepser; E J Ernst; R E Lewis; M E Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Influence of human serum on antifungal pharmacodynamics with Candida albicans.

Authors:  G G Zhanel; D G Saunders; D J Hoban; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods.

Authors:  E J Ernst; M E Klepser; M E Ernst; S A Messer; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1999-02       Impact factor: 2.803

5.  Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.

Authors:  E J Ernst; M E Klepser; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

  6 in total
  49 in total

1.  In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Shana M Gunderson; Robert A Hayes; John P Quinn; Larry H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Serum differentially alters the antifungal properties of echinocandin drugs.

Authors:  Padmaja Paderu; Guillermo Garcia-Effron; Sergey Balashov; Guillaume Delmas; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

4.  Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Authors:  David R Andes; Daniel K Reynolds; Scott A Van Wart; Alexander J Lepak; Laura L Kovanda; Sujata M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

5.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors:  M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

6.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

Review 7.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

8.  Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

Authors:  Emilia Cantón; Javier Pemán; Macrina Sastre; Mónica Romero; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 9.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

10.  Novel concentration-killing curve method for estimation of bactericidal potency of antibiotics in an in vitro dynamic model.

Authors:  Y Q Liu; Y Z Zhang; P J Gao
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.